| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Clearance of amyloid-β (Aβ) from the brains of patients with Alzheimer's disease (AD) has been expected to be a disease-modifying therapy. Microglia are immune cells in the brain and have an ability of Aβ phagocytosis. In this study, we demonstrated that mouse or human bone marrow cells are able to differentiate into microglia-like cells by the stimulation of M-CSF and indicate the ability of Aβ phagocytosis. By the administration of bone marrow cell-derived microglia-like cells into lateral ventricle or tail vain, a part of cells moves to the brain parenchyma. Furthermore, the intra-ventricle injection of the cells decreases brain Aβ level, while the injection from the tail vain does not attenuate the brain Aβ burden and deficit of spatial learning and memory. More efficient delivery of bone marrow-derived microglia-like cells into the brain parenchyma will be the crucial key for the development of the disease-modifying therapy against AD.
|
